Plain-English translation of NCT05813964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a newer HIV prevention approach using emtricitabine and tenofovir alafenamide (TAF/FTC) works as well as an older approach using emtricitabine and tenofovir disoproxil fumarate (TDF/FTC) in preventing HIV infection. Both approaches use "event-driven" dosing, meaning you take pills before and after sexual activity rather than every day. The study will follow participants for up to 3 years to see which approach is most effective, safe, and acceptable.
Current HIV prevention pills require daily dosing, which can be difficult for some people to maintain consistently. This trial explores whether taking pills only around the time of sexual activity — combined with the newer formulation — could be easier to stick with while still providing strong protection against HIV.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to take one of two pill schedules. With the newer schedule, you take one pill 2–24 hours before sex and another pill the next day. With the older schedule, you take two pills before sex, then one pill 24 hours later, and another 24 hours after that. You'll visit the clinic up to 15 times over 1–3 years for check-ups, blood tests, urine tests, and swabs. At the end of the study, you'll transition to HIV prevention services available in your area.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
France
Thailand